Request for Proposals: 2013 ASPIRE Awards in Adult Vaccine Research
The mission of the 2013 ASPIRE Awards in Adult Vaccine Research is to advance medical knowledge to better understand the burden of pneumococcal disease in adults.
The burden of pneumococcal disease in the general adult population has been extensively studied; however, it is not well-defined in special populations, including subgroups with underlying disease comorbidities and/or those living in long-term community settings.
Pfizer invites investigators to apply for the 2013 ASPIRE Awards in Adult Vaccine Research through submission of innovative research proposals for evaluation of the epidemiology and burden of pneumococcal disease in adults with underlying disease comorbidities and/or those living in long-term community settings.
2013 Research Topic
Evaluating the Burden of Pneumococcal Disease in Adults in the United States
An applicant should have a strong research interest within the areas of focus and should consider the following components when developing their research proposals:
A. The burden of pneumococcal disease and serotype distribution in adults including but not limited to:
• Individuals with increased risk of pneumococcal disease including those with underlying comorbidities.
Comorbidities may include but are not limited to:
◦ Diabetes mellitus
◦ Chronic obstructive pulmonary disease (COPD) or other chronic pulmonary disorder
◦ Oncologic disorders
◦ Chronic renal disease
◦ Hepatic disease
◦ Autoimmune disorders
• Those living in community settings (e.g., extended-care facilities, correctional institutions).
• Regional evaluation of pneumococcal resistance and serotype distribution.
• Carriage of Streptococcus pneumoniae in the adult population.
B. Association of pneumococcal pneumonia with influenza or other respiratory viral illnesses
C. The following topics fall outside of the scope of the ASPIRE Adult Vaccine Research Program:
• General education and / or training.
• Support for ongoing clinical programs that are part of an organization’s routine operations.
• Proposals that evaluate populations outside of the United States or Puerto Rico.
Proposals whose primary objective is to financially quantify outcomes as it relates to a Pfizer product(s) are outside the scope of the program.
Within the specified patient populations of interest, investigators are expected to:
• Generate data regarding the burden of pneumococcal disease in adults and/or evaluation of adult vaccination efforts.
• Be able to complete the research in 12 months.
• Present and/or publish the results of the study.
Pfizer is funding research awards up to a maximum of $100,000 USD* each (including direct costs, institutional overhead costs, and indirect costs) for one year to conduct research generating data that will lead to a better understanding of burden of pneumococcal disease in adults.
*Please note that study budgets will be evaluated separately to ensure the requested funding is commensurate with the work proposed.
Deadline for Application
Applications must be received by 11:59pm EST on July 2, 2013.